Company profile: Prevail Therapeutics
1.1 - Company Overview
Company description
- Provider of novel AAV9-based gene therapies for neurodegenerative diseases. Offerings include PR001, delivering a healthy GBA1 gene to correct lysosomal dysfunction in Parkinson's disease with GBA1 mutations and Type 1 Gaucher disease, and PR006, delivering a healthy GRN gene to raise progranulin for frontotemporal dementia.
Products and services
- PR006: A custom-engineered AAV9 gene therapy for frontotemporal dementia with GRN mutations, delivering healthy GRN to increase progranulin and correct lysosomal dysfunction
- PR001: An AAV9-vectorized gene therapy for Parkinson's disease with GBA1 mutations and Type 1 Gaucher disease, delivering healthy GBA1 to correct lysosomal dysfunction
- Novel Gene Therapy Development: A gene therapy–focused program creating therapies for Parkinson's and neurodegenerative diseases, delivering genes to correct lysosomal dysfunction or increase progranulin
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Prevail Therapeutics
Sirna Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology research and development focused on RNA interference (RNAi) for human disease therapy, creating RNAi-based therapies to ultimately treat patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sirna Therapeutics company profile →
Elsie Biotechnologies
HQ: United States
Website
- Description: Provider of RNA therapeutics and oligonucleotide discovery technologies, including a proprietary ultra-high throughput platform that evaluates oligonucleotide chemical space to optimize therapeutic candidates for activity, toxicity, and delivery, and P(V) chemistry technologies with novel reagents and processes to synthesize diverse oligonucleotide therapeutics with complete synthetic control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elsie Biotechnologies company profile →
Neurogene
HQ: United States
Website
- Description: Provider of genetic medicines for neurological disorders, offering EXACT gene therapy technology for controlled and balanced gene expression, a platform that delivers consistent transgene expression (utilized in Rett syndrome) with CNS and ocular delivery, robust CGMP-compliant internal manufacturing for research and clinical material, and clinical trials to evaluate safety and efficacy in genetic diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neurogene company profile →
Cardior Pharmaceuticals
HQ: Germany
Website
- Description: Provider of non-coding RNA-based therapeutics and related tools for heart disease, including CDR132L (Phase 2) to halt and reverse cardiac remodeling after myocardial infarction; clinical trials in heart failure and MI; the CardiorHealth miR-132 PCR kit to measure circulating miR-132; and an H19 gene therapy approach targeting cardiac hypertrophy and heart failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cardior Pharmaceuticals company profile →
Nanogenics
HQ: United Kingdom
Website
- Description: Provider of research-based biotechnology developing artificial viruses for gene therapy. Products include LipTide, a synthetic peptide nanoparticle that mimics natural viruses for targeted RNA delivery to various cell types with low toxicity and repeat dosing, and ECP-105, a glaucoma therapy enhancing trabeculectomy by increasing bleb survival and reducing scarring with a single administration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nanogenics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Prevail Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Prevail Therapeutics
2.2 - Growth funds investing in similar companies to Prevail Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Prevail Therapeutics
4.2 - Public trading comparable groups for Prevail Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →